share_log

Avalo Therapeutics | ARS: Annual Report to Security Holders

Avalo Therapeutics | ARS: Annual Report to Security Holders

Avalo Therapeutics | ARS：年度報告
美股sec公告 ·  06/27 07:08
Moomoo AI 已提取核心訊息
Avalo Therapeutics, a clinical-stage biotechnology company, reported a net loss of $31.5 million for the fiscal year ended December 31, 2023, with negative cash flows from operations amounting to $30.7 million. As of the end of the year, the company had $7.4 million in cash and cash equivalents. During the year, Avalo raised approximately $46.2 million through equity offerings and fully retired its $35 million debt. In March 2024, Avalo acquired AVTX-009, an anti-IL-1β monoclonal antibody, through the acquisition of AlmataBio Inc. Concurrently, Avalo closed a private placement financing for up to $185 million, with an initial investment of $115.6 million and potential additional proceeds of $69.4 million from warrant exercises. The funding is expected to support operations through the anticipated Phase 2 trial results of AVTX-009 in hidradenitis suppurativa in 2026 and into 2027. Avalo's common stock is listed on The Nasdaq Capital Market under the symbol 'AVTX'.
Avalo Therapeutics, a clinical-stage biotechnology company, reported a net loss of $31.5 million for the fiscal year ended December 31, 2023, with negative cash flows from operations amounting to $30.7 million. As of the end of the year, the company had $7.4 million in cash and cash equivalents. During the year, Avalo raised approximately $46.2 million through equity offerings and fully retired its $35 million debt. In March 2024, Avalo acquired AVTX-009, an anti-IL-1β monoclonal antibody, through the acquisition of AlmataBio Inc. Concurrently, Avalo closed a private placement financing for up to $185 million, with an initial investment of $115.6 million and potential additional proceeds of $69.4 million from warrant exercises. The funding is expected to support operations through the anticipated Phase 2 trial results of AVTX-009 in hidradenitis suppurativa in 2026 and into 2027. Avalo's common stock is listed on The Nasdaq Capital Market under the symbol 'AVTX'.
生物技術臨床階段公司Avalo Therapeutics公佈了2023年12月31日結束的財年淨虧損3150萬美元，經營性現金流爲負3070萬美元。截至年末，該公司的現金及現金等價物爲740萬美元。在該年期間，Avalo通過權益發行籌集了約4620萬美元並全額償還了3500萬美元的債務。2024年3月，Avalo通過收購AlmataBio Inc.，收購了抗IL-1β單克隆抗體AVTX-009。同時，Avalo完成了高達1.85億美元的定向增發融資，初始投資爲1.156億美元，額外的可行使權利融資爲6940萬美元。這筆資金預計將支持hidradenitis suppurativa (HS) 項目AVTX-009的2期預計於2026年的試驗結果和2027年的運營。Avalo普通股在納斯達克資本市場上掛牌交易，交易標的爲“AVTX”。
生物技術臨床階段公司Avalo Therapeutics公佈了2023年12月31日結束的財年淨虧損3150萬美元，經營性現金流爲負3070萬美元。截至年末，該公司的現金及現金等價物爲740萬美元。在該年期間，Avalo通過權益發行籌集了約4620萬美元並全額償還了3500萬美元的債務。2024年3月，Avalo通過收購AlmataBio Inc.，收購了抗IL-1β單克隆抗體AVTX-009。同時，Avalo完成了高達1.85億美元的定向增發融資，初始投資爲1.156億美元，額外的可行使權利融資爲6940萬美元。這筆資金預計將支持hidradenitis suppurativa (HS) 項目AVTX-009的2期預計於2026年的試驗結果和2027年的運營。Avalo普通股在納斯達克資本市場上掛牌交易，交易標的爲“AVTX”。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息